Israel Ministry of Health Gives Clearance for Mirror Biologics’ GMP Manufacturing New Facility Design
Mirror Biologics, Inc., a clinical-stage biopharmaceutical company has announced that their GMP manufacturing design for their new facility has received clearance from the Israel Ministry
Immunyx Pharma Selected to Join BLUE KNIGHT™
Immunyx Pharma, a developer of immune modulating therapies for neutrophil-based diseases, has been selected to join Blue Knight, a collaboration between Johnson & Johnson Innovation
Brainsway Treatment of OCD & Depression Utilizing Deep TMS™ Extends Coverage in Washington State
BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, recently announced that a major private insurance
BiondVax’s Inhaled COVID-19 Therapy Virtually Eliminates SARS-COV-2 Virus in Preclinical In Vivo Study!
Hamsters that were infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average
Neteera’s Passive & Contactless Patient Wireless Monitoring Platform Gets FDA Approval!
The Jerusalem-based startup, Neteera Technologies, has spent the last seven years quietly reimagining what healthcare can and should be. Healthcare today is entrenched in wired
Bio-Fence New Paint Additive Destroys Deadly Pathogens
Start-up company Bio-Fence has created an innovative polymer that, when added to a topcoat/paint binds disinfectant to the surface, increasing sanitation efficiency and eliminating pathogenic
FDA Approval For Rafa’s Life-saving Midazolam Autoinjector for US DoD’s Advanced Anticonvulsant System Program
Jerusalem-based Rafa Laboratories LTD. (“Rafa“) is pleased to announce the U.S. Food and Drug Administration has approved its “first in market” 10 mg midazolam autoinjector
eggXYt Brings Ultimate Solution to Prevent Annual Killing of Billions of Male Chicks!
eggXYt, a Jerusalem-based genetic tech startup, has solved the problem of the killing of male chicks and is planning to introduce its technology into the
With Added $25M+ Financing, Nectin Therapeutics Initiates Patient Dosing in Advanced Solid Tumors NTX1088 Phase 1 Trial
Nectin Therapeutics Ltd., (Nectin) a Jerusalem-based biotechnology company developing novel targeted immunotherapies to address resistance to approved immuno-oncology (IO) treatments, started the dosing of the
